You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,287,781


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,287,781
Title: Method for detection of target nucleic acids using PCR
Abstract:A method for detecting the presence of a target nucleic acid sequence in a sample is provided. The method comprises subjecting the sample to an amplification reaction to obtain an amplification product where the target nucleic acid sequence is present using a set of nucleotides, at least one of which is fluorescently labelled. The amplification product is contacted with a probe under conditions in which the probe will hybridise to the target sequence. The probe comprises a reactive molecule which is capable of absorbing fluorescence energy from or donating fluorescent energy to the fluorescent labelled nucleotide. The fluorescence of the sample is monitored and related to the presence of the target nucleic acid sequence. The method can be used to quantitate the amount of target nucleic acid in the sample as well as to determine sequence characteristics. Kits for effecting the method are also provided.
Inventor(s): Lee; Martin Alan (Salisbury, GB), Leslie; Dario Lyall (Salisbury, GB)
Assignee: The Secretary of State for Defence in Her Britannic Majesty\'s Government (GB)
Application Number:09/622,426
Patent Claims:1. A method for detecting the presence of atarget nucleic acid sequence in a sample, said method comprising (a) subjecting said sample to an amplification reaction to obtain an amplification product where the target nucleic acid sequence is present, using a set of nucleotides, at least one of which is fluorescently labeled, (b) contacting the amplification product with a probe under conditions in which the probe will hybridise to said target sequence, said probe comprising a reactive molecule which is capable of absorbing fluorescence energy from or donating fluorescent energy to said fluorescent labeled nucleotide and (c) monitoring fluorescence of said sample; and (d) relating the fluorescence of the sample to detect the presence of the target nucleic acid sequence.

2. A method according to claim 1, wherein in the reactive molecule absorbs fluorescence from said fluorescent labeled nucleotide.

3. A method according to claim 2, wherein the reactive molecule is an acceptor molecule which emits energy at a characteristic wavelength.

4. A method according to claim 3, wherein the acceptor molecule is a rhodamine dye or other dye such as Cy5.

5. A method according to claim 1, wherein the labeled nucleotide is labeled uracil.

6. A method according to claim 1, wherein all nucleotides used in the amplification reaction are labeled.

7. A method according to claim 1, wherein the amplification reaction comprises the polymerase chain reaction (PCR).

8. A method according to claim 1, further comprising: monitoring fluorescent emissions of both the labeled nucleotide and the reactive molecule; and calculating the relationship between the emissions.

9. A method according to claim 1, wherein the probe is present throughout the amplification reaction.

10. A method according to claim 9, wherein the fluorescence is monitored to obtain fluorescence results, wherein the results used to quantitate the amount of target sequence present in the sample.

11. A method according to claim 1, wherein the amplification reaction includes a DNA polymerase, wherein the probe is designed such that it is hydrolyzed by the DNA polymerase used in the amplification reaction.

12. A method according to claim 1, wherein the amplification reaction includes an extension phase, wherein the probe is designed such that during the extension phase of the amplification reaction, the probe is released intact from the target sequence.

13. A method according to claim 12, wherein the amplification reaction is effected using a 5'-3' exonuclease lacking enzyme.

14. A method according to claim 13, wherein the enzyme is Stoffle fragment of Taq or Pwo.

15. A method according to claim 12, wherein the 3' end of the probe is blocked by phosphorylation.

16. A method for detecting nucleic acid amplification comprising: performing nucleic acid amplification on a target polynucleotide in the presence of (a) a nucleic acid polymerase (b) at least one primer capable of hybridizing to said target polynucleotide, (c) a set of nucleotides, at least one of which is fluorescently labeled and (d) an oligonucleotide probe which is capable of binding to said target polynucleotide sequence and which contains a reactive molecule which is capable of absorbing fluorescence energy from or donating fluorescent energy to the said labeled nucleotide; and monitoring charges in fluorescence during the amplification reaction, wherein changes in the fluorescence are indicative of the nucleic acid amplification reaction.

17. A method according to claim 16, wherein the amplification is carried out using a pair of primers.

18. A method according to any one of 1 or 16, "claims" wherein the probe is specific either for a splice region of RNA or an intron in DNA, so that only one of amplified RNA or amplified DNA is detected and/or quantitated.

19. A method for determining a reaction condition at which a sequence hybridizes to or separates from a probe, said method comprising (a) amplifying said sequence using a set of nucleotides, at least one of which is fluorescently labeled, (b) contacting amplification product with a probe under condition in which the probe will hybridize to said target sequence, said probe comprising a reactive molecule which is capable of absorbing fluorescence energy from or donating fluorescent energy to said fluorescent labeled nucleotide and (c)monitoring fluorescence of said sample and determining a particular reaction condition, characteristic of said sequence, at which fluorescence changes as a result of the hybridization of the probe to the sample or destabilization of the duplex formed between the probe and the target nucleic acid sequence.

20. A method for detecting a polymorphisms and/or allelic variation, said method comprising amplifying a sequence suspected of containing said polymorphism or variation using the method as defined in claim 1, to obtain an amplification product, generating a flourescence signal measuring the temperature at which the probe melts from the amplification product using the fluorescent signal generated, and comparing this temperature to the temperature at which a sequence not having a polymorphism and/or allelic variation melts from said probe in order to detect the polymorphism and/or allelic variation.

21. A kit for use in the method of any one of claims 1, 16, 19, or 20, which comprises a fluorescently labeled nucleotide and a probe specific for a target nucleotide sequence, the probe comprising a reactive molecule which is capable of absorbing fluorescence from or donating fluorescent energy to said fluorescently labeled nucleotide.

Details for Patent 6,287,781

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2018-02-19
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2018-02-19
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2018-02-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.